Table 4.

Effect of G-CSF on GVHD, relapse, non-relapse mortality, disease-free and overall survival in patients aged ≥50 years

Outcome	Number Events/Evaluable	Hazard Ratio (95% confidence interval)	p-value
Grade 2-4 acute GVHD*
HCT without G-CSF	138/320	1·00
HCT with G-CSF	162/385	1·03 (0·82 – 1·29)	0·83
Grade 3-4 acute GVHD**
HCT without G-CSF	44/323	1·00
HCT with G-CSF	64/377	1·32 (0·90 – 1·95)	0·15
Chronic GVHD***
HCT without G-CSF	120/325	1·00
HCT with G-CSF	122/380	1·07 (0·83 – 1·39)	0·59
Relapse♯
HCT without G-CSF	109/325	1·00
HCT with G-CSF	124/383	1·16 (0·90 – 1·51)	0·25
Non-relapse mortality╪
HCT without G-CSF	38/325	1·00
HCT with G-CSF	86/383	2·10 (1·43 – 3·08)	0·0002
Disease-free survival∥
HCT without G-CSF	147/325	1·00
HCT with G-CSF	210/383	1·40 (1·14 – 1·74)	0·0017
Overall survival$
HCT without G-CSF	87/325	1·00
HCT with G-CSF	154/383	1·48 (1·15 – 1·92)	0·0024

Abbreviation:

HCT = hematopoietic cell transplant

G-CSF = granulocyte colony stimulating factor

GVHD = graft-versus-host disease

^*Model adjusted for disease

^**Model adjusted for disease and KPS

^***Model adjusted for disease

^♯Model adjusted for disease risk index, KPS and condition regimen intensity

^╪Model adjusted for disease and hematopoietic comorbidity score

^∥Model adjusted for disease risk index, KPS and condition regimen intensity

^$Model adjusted for KPS and hematopoietic comorbidity score